The global cell banking outsourcing market is valued at USD 16.07 billion in 2025 and is projected to reach USD 43.59 billion by 2034, growing at a CAGR of 11.73%. Growth is fueled by rising adoption of stem cell therapies, demand for advanced cell-based treatments, and advancements in cryopreservation technology.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell Banking Outsourcing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell Banking Outsourcing Market, by Type
8.1.1 Master Cell Banking
8.1.1.1. Market Revenue and Forecast
8.1.2. Working Cell Banking
8.1.2.1. Market Revenue and Forecast
8.1.3. Viral Cell Banking
8.1.3.1. Market Revenue and Forecast
9.1. Cell Banking Outsourcing Market, by Cell Type
9.1.1. Stem Cell
9.1.1.1. Market Revenue and Forecast
9.1.2. Non-Stem Cell
9.1.2.1. Market Revenue and Forecast
10.1. Cell Banking Outsourcing Market, by Phase
10.1.1. Bank Storage
10.1.1.1. Market Revenue and Forecast
10.1.2. Bank Characterization & Testing
10.1.2.1. Market Revenue and Forecast
10.1.3. Bank Preparation
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type
11.1.2. Market Revenue and Forecast, by Cell Type
11.1.3. Market Revenue and Forecast, by Phase
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type
11.1.4.2. Market Revenue and Forecast, by Cell Type
11.1.4.3. Market Revenue and Forecast, by Phase
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type
11.1.5.2. Market Revenue and Forecast, by Cell Type
11.1.5.3. Market Revenue and Forecast, by Phase
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type
11.2.2. Market Revenue and Forecast, by Cell Type
11.2.3. Market Revenue and Forecast, by Phase
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type
11.2.4.2. Market Revenue and Forecast, by Cell Type
11.2.4.3. Market Revenue and Forecast, by Phase
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type
11.2.5.2. Market Revenue and Forecast, by Cell Type
11.2.5.3. Market Revenue and Forecast, by Phase
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type
11.2.6.2. Market Revenue and Forecast, by Cell Type
11.2.6.3. Market Revenue and Forecast, by Phase
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type
11.2.7.2. Market Revenue and Forecast, by Cell Type
11.2.7.3. Market Revenue and Forecast, by Phase
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type
11.3.2. Market Revenue and Forecast, by Cell Type
11.3.3. Market Revenue and Forecast, by Phase
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type
11.3.4.2. Market Revenue and Forecast, by Cell Type
11.3.4.3. Market Revenue and Forecast, by Phase
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type
11.3.5.2. Market Revenue and Forecast, by Cell Type
11.3.5.3. Market Revenue and Forecast, by Phase
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type
11.3.6.2. Market Revenue and Forecast, by Cell Type
11.3.6.3. Market Revenue and Forecast, by Phase
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type
11.3.7.2. Market Revenue and Forecast, by Cell Type
11.3.7.3. Market Revenue and Forecast, by Phase
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type
11.4.2. Market Revenue and Forecast, by Cell Type
11.4.3. Market Revenue and Forecast, by Phase
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type
11.4.4.2. Market Revenue and Forecast, by Cell Type
11.4.4.3. Market Revenue and Forecast, by Phase
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type
11.4.5.2. Market Revenue and Forecast, by Cell Type
11.4.5.3. Market Revenue and Forecast, by Phase
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type
11.4.6.2. Market Revenue and Forecast, by Cell Type
11.4.6.3. Market Revenue and Forecast, by Phase
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type
11.4.7.2. Market Revenue and Forecast, by Cell Type
11.4.7.3. Market Revenue and Forecast, by Phase
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type
11.5.2. Market Revenue and Forecast, by Cell Type
11.5.3. Market Revenue and Forecast, by Phase
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type
11.5.4.2. Market Revenue and Forecast, by Cell Type
11.5.4.3. Market Revenue and Forecast, by Phase
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type
11.5.5.2. Market Revenue and Forecast, by Cell Type
11.5.5.3. Market Revenue and Forecast, by Phase
12.1. Bio Outsource (Sartorious)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. BSL Bioservice
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Cryo-Cell International, Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Charles River Laboratories
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. LifeCell
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. GBI
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Lonza
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. SGS Société Générale de Surveillance SA
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Perfectus Biomed Limited
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description